Price of Dutasteride has fallen to the 200 won range

TELCON RF PHARMACEUTICAL's Durid 0.5mg, listed at 267 won

85% of the existing lowest price of 315 won

Non-reimbursed hair loss treatment market is also likely to affect

Original Avodart

The upper limit of Dutasteride products used for prostatic hypertrophy and hair loss has fallen to around 200 won.

 

The effect of cascading drug prices is large, and it is expected to affect the hair loss treatment market.

 

According to industries on the 27th, TELCON RF PHARMACEUTICAL's Durid 0.5mg will be listed at the upper limit of 267 won on the 1st of next month.

 

More than 20 of the same system were applied, 85% of the existing lowest price of the same system (315 won).

 

Dutasteride tablets are evaluated as more convenient formulations than conventional capsule formulations.

 

All 37 currently paid drugs are from domestic pharmaceutical companies.

 

Domestic companies have put forward tablets as a differentiation strategy from Avodart, the original drug containing Dutasteride.

 

Analysts say that it is easier to split and swallow than capsule formulation.

 

As more than 20 are listed at once, the upper limit is gradually falling due to the cascaded drug prices implemented by late pharmaceutical companies since July 2020.

 

The lowest price of 267 won is only 38% of the highest price (709 won).

 

The lowest price for a month on the 30th is 8,010 won, while the highest price is 21,270, a difference of more than 10,000 won.

 

The original Avodart is also 709 won per capsule, the highest price.

 

As such, the falling upper limit of Dutasteride is expected to affect the non-reimbursed hair loss treatment market.

 

This is because low prices are advantageous in the non-reimbursed market.

 

If pharmaceutical companies supply products to nursing institutions in line with the upper limit, hospitals and pharmacies will put a margin based on the upper limit.

 

Therefore, the lower the upper limit, the cheaper the non-reimbursed amount when prescribed for hair loss.

 

Hair loss patients also visit hospitals and clinics that prescribe inexpensive products on purpose, so the lowest price is also helpful for market competition.

 

As a result, it is understood that there are pharmaceutical companies that want to register salaries for competitiveness in the hair loss treatment market even if the upper limit is lowered due to cascaded drug prices.

 

Since Dutasteride drugs are covered by benefits for prostate hypertrophy, most pharmaceutical companies have fewer factors to lower the upper limit.

 

Currently, 28 out of 37 Dutasteride tablets are listed at 709 won, the highest price.

 

It is said that a few pharmaceutical companies deliberately lower the upper limit and sell it as a non-payment for hair loss treatment because supplying it cheaper than the upper limit of the actual transaction price could be lowered.

 

Ten of the same products currently licensed remain non-reimbursed.